A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study-Reference-Cited by-同舟云学术

A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study

Published:2021-01-08 Issue:3 Volume:23 Page:811-821
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Kitazawa Masaru¹,Katagiri Takashi²,Suzuki Hiromi³,Matsunaga Satoshi⁴,H Yamada Mayuko¹,Ikarashi Tomoo⁵,Yamamoto Masahiko¹,Furukawa Kazuo⁶,Iwanaga Midori¹,Hatta Mariko¹,Fujihara Kazuya¹,Yamada Takaho¹,Tanaka Shiro⁷,Sone Hirohito¹

Affiliation:

1. Department of Internal Medicine Niigata University Faculty of Medicine Niigata Japan

2. Kashiwazaki General Hospital and Medical Center Kashiwazaki Japan

3. Niigata Prefectural Shibata Hospital Shibata Japan

4. Niigata Prefectural Chuo Hospital Joetsu Japan

5. Niigata Medical Center Niigata Japan

6. Nagaoka Red Cross Hospital Nagaoka Japan

7. Department of Clinical Biostatistics/Clinical Biostatistics Course Graduate School of Medicine Kyoto University Kyoto Japan

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14288

Reference36 articles.

1. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

2. Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey

3. Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users

4. Addition of dipeptidyl peptidase‐4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta‐analysis;Salvo F;BMJ,2016

5. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pancreatitis and Pancreatic Cancer Risk Among Patients With Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors: An Updated Meta-Analysis of Randomized Controlled Trials;Clinical Therapeutics;2024-08

2. Strategies to address diabetic kidney disease burden in Mexico: a narrative review by the Mexican College of Nephrologists;Frontiers in Medicine;2024-06-19

3. Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials;Expert Opinion on Pharmacotherapy;2024-05-02

4. Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study;Cardiovascular Diabetology;2024-02-08

5. Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study;Clinical Drug Investigation;2023-11-07